Form 4: bioAffinity Technologies Executive Chairman Steven Girgenti Reports Stock Transactions

Executive Chairman Steven Girgenti reports acquisition and disposal of bioAffinity Technologies stock, including a grant of restricted shares and shares held by a trust.

Summary

• Steven Girgenti, Executive Chairman of bioAffinity Technologies, reported transactions involving the company's common stock.
• On January 10, 2025, Girgenti acquired 14,814 shares of common stock through a grant.
• These shares are restricted and will vest pro rata on a monthly basis over 12 months, starting February 10, 2025.
• On the same day, Girgenti disposed of 8,955 shares held indirectly through the Cranye Girgenti Testamentary Trust.
• Following these transactions, Girgenti directly owns 1,080,062 shares of bioAffinity Technologies.
• Girgenti disclaims beneficial ownership of the shares held by the trust, except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of stock transactions. The grant of restricted shares is mildly positive, while the disposal of trust shares is mildly negative, balancing out overall.

Positives

• The grant of restricted shares to the Executive Chairman could be seen as an incentive to align his interests with the company's long-term performance.

Negatives

• The disposal of shares held by the trust, while disclaimed for beneficial ownership, could be perceived negatively by some investors.

Risks

• The vesting schedule of the restricted shares could influence the Executive Chairman's decisions over the next 12 months.
• Any significant changes in ownership by insiders could create uncertainty in the market.

Future Outlook

The vesting of restricted shares over the next 12 months may influence insider activity.

Management Comments

• The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Industry Context

Form 4 filings are standard practice for reporting insider transactions and provide transparency to investors.

Stakeholder Impact

• Shareholders may be interested in the insider transactions as an indicator of management's confidence in the company.

Key Dates

Keywords

bioAffinity Technologies, Steven Girgenti, stock transaction, restricted shares, beneficial ownership, Form 4, BIAF